Category Archives: Stem Cell Research

TORONTO, ONTARIO--(Marketwire - March 12, 2013) - NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES Stem Cell Therapeutics Corp. ("SCT") (TSX VENTURE:SSS), a life sciences company developing stem cell-related technologies, announced today that it has filed its prospectus supplement dated March 11, 2013 in each of the Canadian provinces of British Columbia, Alberta, Manitoba, Ontario and Nova Scotia to SCT's base shelf prospectus of March 1, 2011 in respect of its previously announced offering of securities. The offering consists of up to 14,000,000 units ("Units") which will be offered at $0.25 each for gross proceeds of up to $3.5 million. Each Unit will be comprised of one common share and one common share purchase warrants (the "Warrants"). Each Warrant will entitle the holder to purchase an additional common share for $0.40 for a period of 60 months following the closing of the offering. Euro Pacific Canada Inc. is acting as the agent for the offering. Closing of the offering is expected to occur on or about March 15, 2013 and is subject to customary conditions, including the approval of the TSX Venture Exchange. The purpose of the offering is to provide the resources necessary … Continue reading →

Cellular Therapy and Cord Blood 2013 Market Report is the new market research report added to the ReportsnReports.com store. Dallas, TX (PRWEB) March 12, 2013 The report analysis clinical trial trends and the evolution of several therapeutics areas within cellular therapy [orthopedic, skin/wound care, cardiovascular, and CNS disorders] and present the current status of every single program within the preclinical through the various clinical trial phases and onto commercialization. The report also presents the breakout of clinical trials in the bonafide cellular therapy sector with respect to geographic breakout, breakout by type of cells utilized, and disease classes interrogated. The report Cellular Therapy and Cord Blood 2013 Market Report also provides a detailed quantitative analysis of the cord blood field as it is rapidly evolving. The report provides hard numbers on sizes of the various registries, the TNC breakouts of banked units, detailed cost breakouts for banking as well as HSCTs utilizing cord blood. Furthermore, the report has been able to compare the EU and US markets side-by-side in this analysis. The report also presents the ATMP regulatory guidelines governing the marketing authorization of cellular therapeutics in the European Union. Details on the statute as well as implications to companies … Continue reading →

OMICS Group-Journal of Stem Cell Research Therapy-2157-7633-S7-002 Here we provide intuitive thinking with systems biology view to explain the inevitable heterogeneity of cancer cells as an abnormal cell type driven by dynam... By: OMICSGroup I Articles … Continue reading →

Research focus on investigation of laminin-based approaches BioLamina, Stockholm, Sweden and Roche recently announced the signing of a research and development agreement to jointly develop new cell culture systems for various applications, including stem cell research. The collaboration will focus on assessing laminin-based in-vitro cell culture matrices offering highly physiological microenvironments for living cells. Under the terms of the agreement Roche will provide R&D funding and scientific expertise to BioLamina. Financial details were not disclosed. Laminins are proteins located in the extracellular matrix providing the stability essential for cell growth and behaviour. They are the only protein group in this environment that have a tissue-specific distribution, including expression of specific laminins during embryonic development. This makes them a very interesting target for new biologically relevant cell culturing techniques. Our aim is to develop laminin-based culture systems that provide biologically relevant, standardized environments, said Ruedi Stoffel, Head of Biochemical Reagents & Custom Biotech at Roche. We are looking forward to this collaboration to build on the revolutionary cell cultivation techniques developed by our colleagues at the Karolinska Institute and BioLamina. Were delighted that Roche has recognized the potential of our products and technology, which we believe will significantly complement their expertise … Continue reading →

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/npnqpg/the_market_for) has announced the addition of the "The Market for Stem Cell Research Products: Current and Future Opportunities" report to their offering. The market for stem cell research products continues to flourish. As stem cell research begins to yield actionable therapies, companies are investing resources in this area of research that stands to revolutionize the way many diseases are treated. Pharmaceutical and biotech companies are seeking to leverage portfolios beleaguered by high drug attrition rates and expiring patents, and the use of stem cells in the drug discovery phase, rapid developments in regenerative medicine and the emergence of novel cell based therapies promise to offer exciting new revenue streams. Increasingly, industry and academic institutions are collaborating on stem cell research and product development. But given that practical stem-cell based therapies can take years to develop and are often stalled by heavy regulation, suppliers are in need of gaining a clear understanding of the wide range of products that support the stem cell research that is currently underway in both academic and industrial labs. The Market for Stem Cell Research Products: Current and Future Opportunities, BioInformatics LLC's latest report, was designed to help suppliers assess how … Continue reading →

Public release date: 7-Mar-2013 [ | E-mail | Share ] Contact: Peter Tarr tarr@cshl.edu 516-367-8455 Cold Spring Harbor Laboratory Cold Spring Harbor, NY In collaboration with colleagues at Cornell University, a team of cancer researchers at Cold Spring Harbor Laboratory (CSHL) has discovered cells with stem-cell properties in the ovary that can mutate to form tumors. The team demonstrated that when two important tumor suppressor genes are inactivated, a previously unknown subset of ovarian stem-like epithelial cells undergoes cancerous transformation. The findings, published today in the journal Nature, have important implications for our knowledge about ovarian cancer. "Sources of cells that make ovarian tumors are not really known," says Grigori Enikolopov, Ph.D., one of the co-authors and team leader at CSHL. Dr. Alexander Nikitin is the corresponding author and team leader at Cornel University. "We demonstrated that a stem cell population sits in a portion of the ovary called the hilum, and can repair the ruptures of the ovarian tissue during ovulation, and that these cells are easily transformed into tumor cells," Enikolopov explains. The idea that cells with stem cell properties can spontaneously mutate to become seeds of cancer has been gaining momentum. Some epithelial cancers such as cancers … Continue reading →

REDWOOD CITY, Calif.--(BUSINESS WIRE)-- OncoMed Pharmaceuticals, Inc., a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced that patient dosing has begun in a Phase 1 clinical trial of OMP-52M51 in patients with advanced, refractory solid tumors. OMP-52M51, OncoMeds fifth product candidate, entered clinical testing in hematologic cancers in December 2012 and is now also being tested in patients with selected solid tumors. OMP-52M51 is a proprietary monoclonal antibody that targets the Notch1 receptor. The Phase 1 clinical trial of OMP-52M51 in solid tumors is an open-label dose escalation and expansion study in patients with advanced, refractory solid tumors. These patients will be assessed for safety, pharmacokinetics, pharmacodynamics, and initial evidence of efficacy, and the clinical trial will also assess a predictive biomarker-based patient selection approach. The trial is being conducted at several sites in the United States including the South Texas Accelerated Research Therapeutics (START). According to Dr. Amita Patnaik of START, who treated the first patient with OMP-52M51 on the solid tumor trial, It is exciting to begin a clinical trial with this therapeutic, with a novel anti-cancer stem cell mechanism of action, to patients with advanced solid tumors. The companion … Continue reading →

TORONTO, ONTARIO--(Marketwire - March 7, 2013) - NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S.NEWSWIRE SERVICES Stem Cell Therapeutics Corp. (TSX VENTURE:SSS) ("SCT"), a life sciences company developing stem cell-related technologies, announced todaythat it intends to file a prospectus supplement in each of the Canadian provinces of British Columbia, Alberta, Manitoba, Ontario and Nova Scotia by way of a prospectus supplement to SCT's base shelf prospectus of March 1, 2011 in respect of its previously announced offering of securities. The offering consists of up to 14,000,000 units ("Units") which will be offered at $0.25 each for gross proceeds of up to $3.5 million. Each Unit will be comprised of one common share and one common share purchase warrants (the "Warrants"). Each Warrant will entitle the holder to purchase an additional common share for $0.40 for a period of 60 months following the closing of the offering. Euro Pacific Canada Inc. is acting as the agent for the offering. The purpose of the offering is to provide the resources necessary to conclude the acquisition of Trillium Therapeutics Inc. by SCT, announced February 4th, 2013, and to trigger a condition precedent to permit the exercise of the option … Continue reading →

WALTHAM, Mass.--(BUSINESS WIRE)-- Minerva Biotechnologies, a leading cancer and stem cell development company today announced a major breakthrough in human stem cell research. Minerva scientists converted established human stem cells to the elusive nave state and maintained them there indefinitely simply by culturing the cells in the dimeric form of a natural, but newly discovered human growth factor, called NM23-H1. It is widely believed that figuring out how to stably induce nave pluripotency in human stem cells is critical for realizing the promise of human stem cell therapies. This is very exciting, said Dr. Cynthia Bamdad, Minerva President and Chief Executive Officer, Until now scientists had only been able to temporarily convert human stem cells to the nave state by genetically modifying the cells or by treating the cells with a cocktail of biochemical inhibitors. This appears to be the natural growth factor that keeps stem cells in the truly pluripotent nave state and overcomes what had been a major impediment to developing human stem cell therapies. Scientists have recently become quite interested in getting human stem cells into the ground or nave state because only these cells are truly pluripotent and able to properly differentiate into any cell in … Continue reading →

Posted at: 03/05/2013 5:50 PM By: The Associated Press SANTA FE, N.M. (AP) - A measure to allow human embryonic stem cell research in New Mexico has passed the Senate. The proposal would permit couples with leftover embryos at in-vitro fertilization clinics to donate them for research rather than have a clinic discard them. Supporters, including several Republican lawmakers, say the research may help in finding cures for deadly diseases and repairing damaged tissues, including spinal cord injuries. Opponents object to using human embryos for research. Stem cells are the building blocks for other cells in the body. The legislation was approved by the Senate on a 23-16 vote on Tuesday and goes to the House for consideration. Similar stem cell research proposals passed the Senate but failed in the House several times when Democrat Bill Richardson was governor. (Copyright 2013 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.) Continue reading here: Senate approves stem cell research proposal … Continue reading →